Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, March 5th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter.
Adaptimmune Therapeutics Trading Down 2.0 %
Shares of ADAP stock traded down $0.01 on Friday, hitting $0.54. The company had a trading volume of 1,677,674 shares, compared to its average volume of 1,065,138. The firm has a market cap of $138.18 million, a P/E ratio of -2.45 and a beta of 2.42. The stock's 50-day moving average is $0.59 and its two-hundred day moving average is $0.78. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. Adaptimmune Therapeutics has a twelve month low of $0.51 and a twelve month high of $2.05.
Wall Street Analysts Forecast Growth
ADAP has been the subject of several recent research reports. Guggenheim decreased their price target on Adaptimmune Therapeutics from $4.00 to $3.00 and set a "buy" rating for the company in a research note on Friday, November 15th. StockNews.com cut Adaptimmune Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, November 14th. HC Wainwright cut their target price on Adaptimmune Therapeutics from $4.00 to $3.50 and set a "buy" rating on the stock in a research report on Thursday, November 14th. Finally, Mizuho cut their target price on Adaptimmune Therapeutics from $3.00 to $1.50 and set an "outperform" rating on the stock in a research report on Wednesday, November 27th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $2.79.
View Our Latest Report on ADAP
Adaptimmune Therapeutics Company Profile
(
Get Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Featured Articles
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
